Comparison between low molecular weight heparin and apixaban (novel oral anticoagulant) in prophylaxis against venous thromboembolism after laparoscopic sleeve gastrectomy

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

PACTR

Registry ID

PACTR202410819654281

Enrollment

100

Registered

2024-10-14

Start date

2022-08-04

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Haematological Disorders Surgery

Interventions

Low molecular weight heparin

Apixaban

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Subjects with severe obesity (BMI = 35 kg/m² or = 30 kg/m² with comorbidities), Normal preoperative human coagulation factor Xa serum level, and Normal preoperative mesenteric, portal, splenic, and lower limb venous duplex were recruited.

Exclusion criteria

Exclusion criteria: A history of bariatric surgery other than LSG, A history of VTE/pulmonary embolism, or heart valve replacement, as well as pregnancy, lactation, and Missed follow-up duplex.

Design outcomes

Primary

Measure	Time frame
to assess the efficacy and safety of apixaban compared to LMWH for VTE prophylaxis after laparoscopic sleeve gastrectomy (LSG), by evaluating the incidence of VTE and bleeding.	—

Secondary

Measure	Time frame
The incidence of postoperative complications	—

Countries

Egypt

Contacts

Public ContactAhmed Elansary

Lecturer of general surgery in Cairo University

Ahmed_m_salah@kasralainy.edu.eg+201007267283

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026